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xenograft model for Burkitt lymphoma
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Background: Burkitt lymphoma (BL) is an aggressive malignancy that arises from B-cells and belongs to the group
of Non-Hodgkin lymphomas (NHL). Due to the lack of appropriate in vivo models NHL research is mainly performed
in vitro. Here, we studied the use of the chick chorioallantoic membrane (CAM) for the generation of human BL
xenograft tumors, which we compared with known characteristics of the human disease.
Methods: In order to generate experimental BL tumors, we inoculated human BL2B95 and BL2-GFP cells on the
CAM. BL2B95 xenograft-tumors were grown for seven days and subsequently analyzed with transmission electron
and immunofluorescence microscopy, as well as histological staining approaches. BL2-GFP cells were studied at
regular intervals up to seven days, and their metastatic behavior was visualized with intravital immunofluorescence
techniques.
Results: Xenografted BL2B95 cells formed solid tumors in the CAM model with a Ki67-index greater than 90%,
preservation of typical tumor markers (CD10, CD19, CD20), a ‘starry sky’ morphology, production of agyrophilic fibers
in the stroma, formation of blood and lymphatic vessels and lymphogenic dissemination of BL2B95 to distant sites.
We identified macrophages, lymphocytes and heterophilic granulocytes (chick homolog of neutrophils) as the most
abundant immune cells in the experimental tumors. BL2-GFP cells could be traced in real-time during their
distribution in the CAM, and the first signs for their dissemination were visible after 2-3 days.
Conclusions: We show that xenografted BL2B95 cells generate tumors in the CAM with a high degree of cellular,
molecular and proliferative concord with the human disease, supporting the application of the CAM model for NHL
research with a focus on tumor-stroma interactions. Additionally we report that BL2-GFP cells, grafted on the CAM
of ex ovo cultured chick embryos, provide a powerful tool to study lymphogenic dissemination in real-time.
Keywords: Non-Hodgkin lymphoma, Angiogenesis, Lymphogenic metastasis, BL2, BL2B95, Tumor-stroma
interaction, Microenvironment, Macrophages, GranulocytesBackground
The term Non-Hodgkin-lymphoma (NHL) describes all
malignant diseases of the lymphatic system not belonging
to the class of Morbus Hodgkin. The distinction between
Morbus Hodgkin and NHL is based on the occurrence of
multinucleated Sternberg-Reed cells. When these are de-
tected in microscopical examinations, the malignancy is
classified as Morbus Hodgkin lymphoma. Various factors
can lead to the formation of NHL, including chromosomal
translocations and viral infections. NHL can be further sub-
divided according to the affected cell type into B- and T-* Correspondence: joerg.wilting@med.uni-goettingen.de
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distribution, and reproduction in any mediumcell lymphomas. In this study we analyzed the NHL subtype
Burkitt lymphoma (BL), which arises from B-cells. BL is a
very rare, aggressive disease with an incidence rate of ap-
proximately 0.2 per 100.000/year [1]. The malignancy is di-
vided into three subgroups and often associated with the
Epstein-Barr-Virus (EBV), which drives transformation [2].
BL was first described by Denis Burkitt in 1958, and this
subtype is nowadays considered as the endemic, equatorial
African form of the disease [3]. In this study we used the
well established BL2 cell line, and a derivative of this, which
was in vitro infected with EBV serotype B95-8 [4]. The BL2
cell line was initially isolated from a Caucasian patient with
multiple metastases, which involved the central nervousntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited.
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sents a sporadic but aggressive subtype of BL [5].
Although there is a good chance of cure for NHL patients
treated with stringent chemotherapeutic regimens, there
are a small percentage of cases that are resistant to therapy
[6,7]. These patients cannot be identified by studies of iso-
lated tumor cells, and it is assumed that there are specific
tumor-stroma interactions that render lymphoma cells re-
sistant to chemotherapy. There are mouse models to study
the interactions of lymphomas with their microenviron-
ment [8], but it appears unlikely that mouse models can be
performed in sufficiently high quantities that allow global
systems-biological analyses of tumor-stroma interactions
with and without divers chemotherapeutic regimens. We
have recently shown that BL cell lines can successfully be
inoculated on the chick chorioallantoic membrane (CAM)
[9,10]. Several CAM experiments described in detail the
tumor microenvironment and the metastatic dissemination
of various tumor entities including melanoma, glioma,
fibrosarcoma and colon carcinoma [11-13]. This underlines
the upcoming role of the CAM model in cancer research,
especially in the field of tumor-stroma interactions and the
analysis of the metastatic cascade. Experiments based of the
CAM-tumor model appear to be highly suited to study the
aforementioned aspects due to the fact that the CAM pro-
vides the presence of nearly all relevant stroma factors, e.g.
immune cells, extracellular matrix components, blood and
lymphatic vessels.
The formation of the CAM starts around day 4 of chick
embryo development. It is an extra-embryonic organ, which
develops by the fusion of the chorion with the vascularized
allantoic membrane. The CAM is responsible for the gas
exchange of the embryo and for that reason very well per-
fused. It shows a high density of blood and lymphatic ves-
sels, which explains its main usage as a model for
angiogenesis [14]. In addition, the CAM is also established
as an animal model for cancer research [9,11,15]. However,
very few studies have dealt with the CAM in the context of
hematological malignancies [16-18], and, to the best of our
knowledge, there are no studies characterizing the host leu-
kocytes that infiltrate the grafted tumors. Previous experi-
ments in our lab showed that the BL cell line, BL2B95,
develops tumors in the CAM that exhibit high similarities
to human BL [9,10]. Here, we followed up on these studies
and validated the usefulness of the CAM model for lymph-
oma research. We show a high degree of molecular and
morphological concord, including tumor-stoma interac-
tions, with the human disease, supporting the application
of the CAM as an in vivo model for NHL research.
Methods
Cell culture
The Burkitt lymphoma cell lines BL2B95 were cultured in
BL-medium (RPMI 1640 medium with 10% FCS, 1%penicillin/streptomycin, 10 mM HEPES, 1 mM sodium-
pyruvate, 50 μM α-thioglycerol and 20 nM BCS). Cells
were cultured in cell culture flasks and incubated at 37°C
and 5% CO2. BL2-GFP (BL-2 ns-c* GFP) cells were cul-
tured in RPMI 1640 with 10% FCS and 1% penicillin/
streptomycin.
Stable transduction of GFP
A self-inactivating lentivirus was prepared by transient
transfection of 293 T cells using calcium phosphate pre-
cipitation method. Briefly, pGIPZ ns-control (Thermo
Scientific, Schwerte, Germany) encoding GFP and a
non-silencing control shRNA (ns-c) was co-transfected
with packaging vector pCMVΔr8.91 and envelope vector
pVSV-G in a ratio of 3:2:1 into 293 T cells. After har-
vesting and determination of titer, lentivirus supernatant
was added to BL2 cells at a MOI < 1 in the presence of
10 μg/ml protamine sulfate, and samples were centrifuged
for 1.5 h at 850 g and 37°C. After 2 days 1 μg/ml puro-
mycin was added to select stably transduced cells express-
ing GFP. The GFP expression in puromycin-resistant cells
was analyzed with a flow cytometer and, when the cells
were positive, they were expanded (Additional file 1:
Figure S1).
CAM assay with BL2B95 cells
Fertilized White Leghorn chick eggs were incubated at
80% relative humidity and 37.8°C. The eggs were win-
dowed at day 3 and the window was sealed with cello-
tape. At day 10 of chick development, one million
BL2B95 cells/egg were applied on the CAM. Cells were
resuspended in 50% BL-medium and 50% Matrigel and
incubated for 30 min at 37°C, 5% CO2 before applying
them on the CAM. The tumors were dissected on day
17 of chick development. Tumors were fixed in 4% para-
formaldehyde for 15 min, washed thrice in PBS and
transferred into 10% sucrose for 3 h at 4°C and 30% su-
crose overnight at 4°C. Tumors were then embedded in
tissue freezing medium and cut with a cryotome into 4-
12 μm thick sections. The experiments were performed
according to the guidelines of the European Parliament
(2010/63/EU) and the council for the protection of ani-
mals in science (§14 TierSchVersV).
CAM assay (ex ovo) with intravital imaging of BL2-GFP
cells
Specific pathogen free fertilized White Leghorn chick eggs
were incubated for 72 h at >80% relative humidity and
37.8°C. On developmental day 3 the eggs were cracked
open and the embryo was carefully transferred into a plastic
square weighing boat (89×89×25mm) and cultured until
day 17 of embryonic development (Additional file 2: Figure
S2 A-G). The weighing boat was placed in a tissue culture
flask with a re-closable lid (Additional file 2: Figure S2 H).
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ensure sufficient humidity. On day 10, 106 BL2-GFP cells in
varying percentages of Matrigel (10-50%) or without Matri-
gel were inoculated on the CAM (Additional file 3: Figure
S3). The embryos were incubated until day 17 in the above
mentioned conditions (>80% rh, 37.8°C). Pictures were
taken every 24 h with Leica MZ16FA microscope. Proce-
dures were adopted from [13]. The experiments were per-
formed according to the guidelines of the European
Parliament (2010/63/EU) and the council for the protection
of animals in science (§14 TierSchVersV).
Histological staining
HE, panoptic Pappenheim, Trichrome and Gomori silver
staining were performed according to standard proce-
dures [19].
Transmission electron microscopy
Specimens with an approximate volume of 600 mm3
were fixed with Karnovsky fixative for at least two hours,
washed in 0.15 M phosphate buffer for 10 min, trans-
ferred into osmium tetroxide solution and incubated for
2 h at 4°C. Then the samples were rinsed with 0.15_M
phosphate buffer for 10 min and subsequently dehy-
drated in an ascending ethanol series of 30%, 50%, 70%,
90% and two times absolute ethanol for 10 min each.
Next the samples were incubated twice in 100% propyl-
ene oxide for 10 min at 4°C. They were then incubated
for 1 h at 4°C in 50% propylene oxide and 50% glycid
ether, transferred into 25% propylene oxide and 75% gly-
cid ether and incubated over night at 4°C. Then the
samples were embedded in epon embedding solution
and incubated for 24 h at 60°C. The embedded tissue
was cut with an Ultracut E microtome (Reichert-Jung)
to 90 nm sections and transferred onto formvar-coated
grids. After air-drying samples were incubated 10 min in
1% uranyl acetate solution, 10 min in lead citrate (Reyn-
olds) and rinsed with purified water. Specimens were an-
alyzed with a Leo 906E (Zeiss) transmission electron
microscope.
Immunofluorescence analyses
Immunofluorescence staining of specimens was performed
by incubation for 1 h with blocking reagent (PBS, 1% BSA,
5% goat serum, 0.2% Triton X-100), 1 h incubation of pri-
mary antibody diluted in antibody solution (TBS [0.05 M,
pH 7.2-7.4], 1% BSA, 0.5% Triton X-100) and 1 h incuba-
tion of secondary antibody diluted in antibody solution
mixed with DAPI (1:10,000). After every step specimens
were rinsed thrice with PBS. Samples were mounted with
Fluoromount-G (Sigma-Aldrich) and dried over night at
room temperature. Stained specimens were studied with
Zeiss Axio Imager.Z1 (Carl Zeiss Goettingen) and filter sets
38HE, 43, 49 and 50. Primary antibodies were rabbit-anti-human Prox1 (Relia Tech) at a 1:500 dilution, mouse anti-
human HLA A,B,C (BioLegend) at 1:200 dilution and
mouse anti-Mep21 (chick CD34 homolog; M. Williams,
AbLab) at dilution of 1:100. Secondary antibodies (Invitro-
gen) were Alexa Fluor® 594 goat anti-mouse IgG (H + L),
Alexa Fluor® 488 goat anti-rabbit IgG (H+ L), Alexa Fluor®
660 goat anti-rabbit IgG (H + L), highly cross-adsorbed;
Alexa Fluor® 594 goat anti-mouse IgG2a (γ2a); Alexa Fluor®
488 goat anti-mouse IgG1 (γ1); at a dilution of 1:200 in
antibody solution.
Immunohistolochemical analyses
Cryosections were fixed in 100% methanol for 3 min, incu-
bated for 3 min in TBS/0.1% Tween, and transferred into
3% H2O2. Specimens were then washed thrice in TBS/0.1%
Tween, blocked with PBS/1% BSA. Subsequently anti-Ki67
antibody was added (rabbit mAb, clone D3B5, Cell Signal-
ing Technology, Danvers, MA, USA) at a concentration of
1:200 (diluted in PBS/1% BSA) and incubated over night at
4°C on a rocking table. Specimen were then washed thrice
with TBS/0.1% Tween, secondary HRP-conjugated goat-
anti-rabbit antibody (St. Cruz Biotechnology, Heidelberg,
Germany) was added at a concentration of 1:200 (diluted in
PBS/1%BSA) and incubated for 30 min at room
temperature. After that the sections were washed thrice
with TBS/0.1% Tween, incubated for 5 min in TrisHCl-
buffer/0.125% ammonium sulfate/0.05% DAB/0.015%
H2O2 and washed with tab water. Section were then coun-
terstained with 0.1% nuclear fast red-aluminum sulfate so-
lution (Merck Millipore, Darmstadt, Germany), washed
with tab water, incubated twice in 100% ethanol for 3 min,
and incubated twice in xylene for 3 min. Samples were
mounted with DePeX (Serva, Heidelberg, Germany). Stain-
ing with antibodies against CD20, CD19, CD10, CD5, TdT
(IR604, IR656, IR648, IR082, IR001; Dako, Hamburg,
Germany), and HLA A,B,C (BioLegend) was performed as
described above except for the counterstaining, which was
performed with hematoxylin, but omitted for CD10 and
HLA.
Western blot
Immunoblot analyses were performed as described pre-
viously [20]. Bcl-6 antibody was obtained from Cell Sig-
naling, c-Myc antibody was from Abcam, alpha-Tubulin
antibody was from Millipore.
3H thymidine assay
Proliferation of cell lines was assessed using 3H thymi-
dine incorporation assay as recently described [10].
Results
Tumor formation
BL2B95 were inoculated on the CAM of day-10 chick
embryo development. The embryos were sacrificed after
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observed that BL2B95 cells formed solid tumors on the
CAM in 100% of the experiments (n = 63). Tumors
formed by BL2B95 assumed a lentiform shape and var-
ied in color between reddish (highly vascularized) and
whitish (sparsely vascularized) (Figure 1A). BL2-GFP
cells formed tumors on the CAM, too, but showed uni-
formly a more whitish color (n = 11), suggesting a higher
angiogenic potential of the EBV-transduced cells.
Histological characteristics of experimental BL-tumors
Tumor cryosections were analyzed with classical histo-
logical staining protocols including HE, panoptic Pappen-
heim, Trichrome and Gomori silver staining. A modified
protocol of the panoptic Pappenheim stain illustrated the
immigration of chick leukocytes into the tumor periphery
(Figure 1A, B). Thereby, chick macrophages possessed aFigure 1 Histological staining of BL2B95 tumors on CAM. A (upper pa
can be divided into a dark stained zone and a central necrotic/hemorrhagi
part: Photopgraphs of BL2B95 tumors. B: Panoptic Pappenheim staining of
appears grayish blue with two blood vessels (bv) in the center of the pictu
clearly visible due to their numerous reddish granules (arrows). Scale bar =
of BLs with tingible body macrophages (arrows and insert). Scale bar = 100
proportion (green) of BL2B95 tumors. Scale bar = 100 μm. E: Ki67 immunoh
Insert shows negative control. Scale bar = 200 μm. F: Gomori silver staining
indicate agyrophilic fibres. Scale bar = 100 μm.light-blue cytoplasm and reddish granules, whereas the
BL2B95 cells stained dark-blue (basophilic) and were con-
siderably larger than the chick leukocytes. We observed
that the borders of the tumors were seamed by immigrating
chick macrophages. They were discernible as lightly stained
cell clusters in the dark-blue BL2B95 tumor mass. The
hematoxylin and eosin staining, too, revealed a ‘starry sky’
appearance of the tumor, consisting of dark and lightly
stained areas (Figure 1C). The chick macrophages were vis-
ible as light cells loaded with cellular debris and apoptotic
tumor cells. This ‘starry sky’-like appearance does reflect
the characteristics of human BL histology and shows that,
like the primary tumors, the experimental tumors largely
consist of BL2B95 cells and interacting leukocytes. Tri-
chrome staining of the tumor specimens showed that they
contained small portions of connective tissue, which, upon
further analyses by silver staining, was characterized byrt): Panoptic Pappenheim staining of tumor cryosections. The tumor
c area surrounded by the non-infiltrated CAM. Scale bar = 1 mm. Lower
tumor/CAM border. BL2B95 cells show dark basophilic cytoplasm. CAM
re. The tumor periphery is infiltrated by chick leukocytes, which are
200 μm C: HE staining of tumors shows classical ‘starry sky’ appearance
μm. D: Trichrome staining shows the small connective tissue
istochemical staining. More than 90% of the tumor cells are Ki67+.
of a tumor area with massive chick leukocyte infiltration; black fibres
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during the staining procedure. Agyrophilia is a feature of
type-III collagen, which is characteristic of lymphatic tissues
and areas of active inflammatory reactions. Ki67 staining of
the experimental tumors showed a mitotic index greater
than 90% (Figure 1E). The immunohistochemical staining
with established BL markers showed that the tumor cells
show the characteristic pattern of classical BL. The experi-
mental BL2B95 tumors were positive for CD20, CD19, and
CD10 (Figure 2A-C). CD5 and TdT staining turned out to
be negative (Figure 2D, E). HLA, which was used to differ-
entiate between human and chick cells, clearly stained all
BL cells (Figure 2F).
In order to characterize in greater detail the chick leuko-
cytes, which immigrated into the BL2B95 tumors, we per-
formed transmission electron microscopy (TEM)-based
analyses (Figure 3A-D). The studies confirm that the tu-
mors consisted mainly of BL2B95 cells and chick leukocytes
(Figure 3A). BL2B95 cell nuclei often presented condensed
or precondensed chromosomes, revealing high mitotic ac-
tivity (Figure 3C, D). The nuclei of the tumor cells wereFigure 2 Immunohistochemical staining on BL2B95 tumors on the CA
BL2B95 tumors 7 days after inoculation on the CAM, counterstained with h
right corner show negative controls. White arrows indicate blood vessels. A
bar = 80 μm. The tumors are positive for CD20, CD19, CD10 and HLA A,B,Cmainly euchromatic with one or several prominent nucleoli.
The cytoplasm possessed a lower electron density com-
pared to the chick leukocytes and appeared therefore
lighter in the TEM pictures. Lipid vesicles in the BL2B95
cell cytoplasm and plasmalemmal microvesicles were also
observed, showing that the BL cells maintained their initial
morphologic features in the CAM model (Figure 3A, C, D).
The identification of chick leukocyte subgroups was per-
formed according to morphological criteria and revealed
the presence of dendritic cells, macrophages and heterophi-
lic granulocytes (chick granulocytes corresponding to hu-
man neutrophils) within or in close proximity to the
BL2B95 tumors (Figure 3A-D). In accordance with previous
studies, lymphogenic dissemination of BL2B95 cells was
also observed with this method [9,10]. Thereby the tumor
cells often filled the lumen of lymphatic vessels completely
(Figure 3C, D).
Lymphatic dissemination of BL cells
The lymphatic dissemination of BL2B95 cells was analyzed
by immunofluorescence staining of tumor cryosections andM. A-F: Immunohistochemical staining of cryosections (8 μm) of
ematoxylin (C and F were not counterstained). Inserts in the lower
: CD20, B: CD19, C: CD10, D: CD5, E: TdT, F: HLA A,B,C. Scale
, but negative for CD5 and TdT.
Figure 3 Transmission electron microscopy of BL2B95 tumors on the CAM. A: BL2B95 cells applied on the CAM form tumors infiltrated by
granulocytes (black arrows). Apoptotic cells are found in the tumors (white arrows). B: Some tumor cells are phagocytized by macrophages (φ).
Tumor cells are completely surrounded by pseudopodia and undergo apoptosis (left white arrow shows late stage apoptotic cell; right white
arrow shows tumor cell in early apoptosis with cytosolic vacuolization). Black arrow shows a lymphocyte in close proximity to the macrophages.
Insert shows higher magnification of Birbeck granules, which identify the cell in the rectangle as a dendritic cell. C: CAM stroma with lymphatic
(lv) and blood vessels (bv) in the tumor periphery. The lumen of the lymphatic vessel is completely filled with BL2B95 cells and chick leukocytes;
black arrows indicate granulocytes. The black rectangle indicates the area magnified in the insert, showing a macrophage with phagosomes of
different maturation stages. D: Lymphatic vessel in the tumor center. The white arrow shows an apoptotic cell. The black arrow shows a
granulocyte, which is magnified in the insert. The nucleus of the granulocyte is bi-lobed and the cytoplasm filled with rod-shaped granules. This
characterizes the cell as a heterophilic granulocyte, which form the most abundant subgroup of granulocytes in the experimental tumors.
(m =mitotically active cell, precondensed chromosomes). Scale bars (A-D) = 10 μm.
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visualized with anti-HLA-antibodies and lymphatic vessels
with lymphatic endothelial cell (LEC)-specific anti-Prox1
antibodies (staining of LEC nuclei). The borders of the tu-
mors appeared fuzzy and several lymphoma cells migrated
into the stroma of the CAM, confirming our previous ob-
servations [9]. Our analyses of tumor sections showed that
BL2B95 cells infiltrated lymphatic vessels both within the
tumors (Figure 4A) and in the vicinity of the tumors. Add-
itionally, whole-mount and cryosection staining showed
that BL2B95 cells migrated long distances and were
found in lymphatic vessels several millimeters apart
from the primary tumors (Figure 3C, D; Figure 4D;
Figure 5). The dissemination along lymphatics was even
more clearly shown for the BL2-GFP cell line (Figure 6;
Additional file 3: Figure S3). BL2-GFP cells were visual-
ized with intravital GFP imaging. Pictures were taken
every 24 h, beginning 48 h after the inoculation (day 12of embryonic development). The time lapse image ar-
rangement demonstrates the migratory routes of BL2-
GFP cells along the outside of the CAM blood vessels
(Figure 6; Additional file 3: Figure S3). The cells were
often arranged in a characteristic pattern along the
blood vessels, which overlays perfectly with the
localization of the lymphatic vessels within the CAM.
Immunofluorescence staining of the CAM revealed that
blood vessels are often flanked by lymphatic vessels on
each side (Figure 4D; Additional file 4: Figure S4). Of
note, this technique allows to study the distribution of
single GFP+ lymphoma cells within the CAM tissue in
real-time. The CAM is lucent enough to trace even
cells, which have migrated into deeper layers of the
CAM, provided that the cells show a strong GFP ex-
pression. Thereby, the density of the Matrigel, which
was used for the inoculation, was found to influence the
timing of the immigration into the CAM stroma and
Figure 4 Immunofluorescence staining of BL2B95 tumors on CAM. A: Immunofluorescence staining of tumor cryosections, merged picture
of four channels. Cells were stained with DAPI (blue), anti-Prox1 (green), anti-HLA A,B,C (red), and anti-MEP21 (yellow). Prox1 stains nuclei of
lymphatic endothelial cells, HLA A,B,C probes BL2B95 cells, and MEP21 stains blood vessels (bv). B: Green channel of A showing anti-Prox1 staining
of nuclei of LECs. C: Yellow channel of A showing anti-MEP21 staining. Capillaries (arrows) and larger blood vessels (bv) are visible. D: Immuno-
fluorescence staining of a whole mount specimen showing a region approximately 1 cm apart from the solid tumor. Merged picture of three
channels. The sample was stained with DAPI (blue), anti-Prox1 (LECs, green), and anti-HLA A,B,C (tumor cells, red). Blood vessels appear as blue
lines due to nucleated chick erythrocytes. Note specific localization of tumor cells in lymphatics. Insert: Higher magnification of boxed area. Scale
bars (A-C) = 100 μm; Scale bar (D) = 100 μm.
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showed much lesser infiltration of lymphatics compared to
cells, which were inoculated with 10% and 0% Matrigel
(Table 1). This is most probably caused by the matrix-
metalloprotease (MMP)-independent (amoeboid) migratory
mode of lymphoma cell lines, which impedes migration
through a collagen-rich matrix.Figure 5 Immunofluorescence staining of metastatic foci in experime
cryosections from experimental BL2B95 tumors. Pictures show BL2B95 cells
A, E), anti-HLA A,B,C (red in B, F) and anti-Prox1 (green in C, G). A, E: BL2B
allantoic epithelium. Ch, chorionic epithelium. B, F: HLA A,B,C staining of B
staining of chick lymphatic endothelial cells. D, H: Merged pictures. Arrows
100 μm in H.Lymphatic and blood vessel formation
The determination of the lymphatic and blood vessels
was performed by immuno-fluorescence (IF) on experi-
mental BL2B95 tumors. Blood vessels were detected
with MEP21 (CD34 homolog) antibody staining, which
is a marker for chick blood endothelial cells (BECs). The
lymphatic vessels were immunostained in cryosectionsntal BL2B95 tumors. A-H: Immunofluorescence staining of
in lymphatic vessels of the CAM. Cells were stained with DAPI (blue in
95 cells can be clearly discriminated due to their large nuclei. Al,
L2B95 cells identifies human cells in the chick stroma. C, G: Prox1
show BL2B95 cells in CAM lymphatics. Scale bars = 50 μm in D, and
Figure 6 Intravital imaging of BL2-GFP cells in the ex ovo CAM model. A-E”: Time lapse images of BL2-GFP cells, which were grafted in 10%
Matrigel on the ex ovo CAM. BL2-GFP cells show a bright green fluorescence, CAM tissue a weak greenish autofluorescence, and blood vessels
appear black. Pictures were taken every 24 h, beginning 48 h post inoculation (p.i.). The magnification of the pictures is indicated. The yellow
rectangles mark regions shown at higher magnification in B-E. The white dotted line in A and A” depicts the region of initial inoculation. Note
the dissemination of tumor cells along vascular routes (white arrows).
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LECs. The IF analyses revealed prominent MEP21+ and
Prox1+ vessels in all BL2B95 tumors (Figure 4B, C). This
clearly shows an interaction of both types of vessels with
the BL2B95-derived tumors and indicates the secretion
of hem- and lymphangiogenic growth factors by the tu-
mors. The presence of blood vessels within the BL2B95
tumors was also observed in the histological stainings,
shown in Figure 2. In contrast, BL2-GFP derived tumors
showed a lesser degree of vascularization and appeared
therefore more whitish.Table 1 Formation of metastatic foci (MF) dependent on
the proportion of matrigel, used in the inoculation
process
Percent matrigel Mean No. of MF Variance n
50 0.25 0-1 4
10 2.3 1-5 3
0 0.25 0-1 4Discussion
Our investigations of BL cells in the chicken CAM
model show a great degree of conformity with the hu-
man disease. BL cells formed solid tumors and dissemi-
nated in the animal mainly via the ECM and the
lymphatics to distant sites. This is the same behavior as
in the human and underlines that the CAM is a highly
suited model to investigate the initial steps of BL-stroma
interactions and the metastatic behavior even of single
tumor cells.
Tumor interactions with various cellular components in
the CAM are highly reminiscent of human BL. HE staining
showed that the BL2B95 cells form tumors with a ‘starry
sky’-like appearance, caused by ‘tingible body macrophages’,
which are scattered in the tumors at regular intervals. This
is extremely significant because the ‘starry sky’ is the major
histological characteristic of BL in humans [21]. Further-
more we were able to identify the involvement of various
chick leukocytes in the BL2B95 tumor formation. Trans-
mission electron microscopy (TEM) depicted the presence
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mammalian neutrophils, which, besides macrophages, are
the most abundant leukocytes in the tumors. This is in con-
cord with findings of previous studies performed in the
CAM [22]. Additionally we found dendritic cells in the
tumor, which formed cell-cell contacts with other avian leu-
kocytes, indicating an active immune response of the host.
Altogether our findings depict a highly complex tumor-
stroma interaction in the CAM model, which can at least
partly simulate the situation in the human disease [23].
The formation of blood vessels and lymphatics in the
BL2B95 tumors is an additional characteristic, which un-
derlines the highly complex tumor microenvironment in
this model. Although we found a varying degree of angio-
genesis in the EBV-transduced BL2B95 tumors, the degree
of vascularization appeared to be higher than in the EBV-
negative BL2 tumors. It is likely that the virus modulates
the composition and quantity of immigrating leukocytes,
which then secrete angiogenic and lymphangiogenic growth
factors. The production of such factors by neutrophils and
macrophages has frequently been shown [24]. The variabil-
ity of the vessel density in tumors derived from the same
cell line makes quantitative assessments more laborious
than in genetically homogenous, inbred, mice; but this
probably better reflects the intra- and inter-individual het-
erogeneity of human tumors. Although the CAM is an em-
bryonic organ and the immune system of the host is in the
process of development, the main components of theTable 2 Characteristics of BL tumors in chick and mouse xeno
Feature/host Chick (CAM xenograft)
Characteristics o
Formation of solid tumors +[9,17,26]
Lymphogenic dissemination +[9] (Figures 3, 4, 5 and 6)
Distant organ metastasis Not yet reported
Macrophage infiltration of tumor
(‘starry sky’)
+ (Figures 1E, F; 3A)
Tumor cell morphology -Blast-like
-Basophilic cytoplasm
-Lipid vacuoles
-Prominent nucleoli (Figures 1, 2, 3, 4 a
Lymphatic/blood vessel formation + [9] (Figure 4B, C)/+[18]
Ki67+% of tumor cells >90% (Figure 1E)
Experimental p
Immune status of host Weakly immunocompetent (develop
immune system)
Investigation period Max. 8 -9 days
Bureaucratic efforts None*
Premises Incubator, Cell culture and imaging de
Costs/n 2 $
*According to German protection of animals act.immune system are present, which may render the model
superior to immunocompromised mouse models.
Despite the species barrier and the embryonic envir-
onment, human BL cell lines acquire many of the
morphological characteristics, and retain the molecular
characteristics, of primary lymphomas when grafted on
the chicken CAM. Besides the typical starry sky morph-
ology, the stroma turns into the typical stroma of
lymphoid organs, with production of agyrophilic fibers.
The morphological features of the BL cells, such as the
production of microvesicles, remains unaltered. The B-
lymphocyte antigens CD19 and CD20, as well as nepri-
lysin (CD10), which is characteristic of early B-cells, are
positive in the CAM lymphomas. The proliferation
index of the experimental tumors is greater than 90%
(Ki67), which is again a major feature of human BL [25].
The development and maintenance of so many lymph-
oma characteristics substantiates the comparability of
the CAM-tumor model with the human disease, and
provides the basis for the transferability of the experi-
mental results to the human.
An additional focus of this study was the metastatic
spread of the BL cells in the CAM. After dissection of
the CAM, we were able to visualize BL2B95 cells in
the stroma and abundantly in lymphatic vessels by im-
munofluorescence staining and TEM. BL2B95 cells are
present in the lymphatics at great distances from the
primary inoculation site. The BL2B95 cells that havegraft models compared to the human disease







-Basophilic cytoplasm - Basophilic cytoplasm
-Lipid vacuoles -Lipid vacuoles
nd 5) -Prominent nucleoli [33] -Prominent nucleoli [34]
-/+[18] +[35]/+[36]
>90% [31] 90-100% [37]
arameters
ing Immunodeficient (depletion of
B- and T-cells)
Mature immune system
Weeks - months Weeks - years
Medium (Animal experiment) High (Clinical trial)




100 $[38] −11000 $[39]
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lumen of lymphatics. This indicated that the cells had
spread via the lymphatics to distant sites. To validate
this observation, we applied an intravital real-time im-
aging approach with BL2-GFP cells. BL2-GFP cells
showed the same migration pattern in the CAM as the
BL2B95 cells. Single BL2-GFP cells could be seen leav-
ing the tumor as early as 2 days after inoculation, pro-
viding evidence for early micrometastasis formation.
The cells thereby migrated along the outside of CAM
blood vessels, which is the typical localization of CAM
lymphatics. Only one or two days later, the formation of
metastases can be observed at distant sites. In numerous
specimens, no significant numbers of tumor cells were
present between the metastatic foci and the primary tu-
mors, strongly indicating that the distant foci are the re-
sult of lymphogenic spread. Nevertheless, migration of
BL2-GFP cells in the ECM adjacent to the primary
tumor occurred as well, but the cells migrated only
shorter distances. It may be of interest to study if the
travelling of cells within CAM lymphatics is restricted
to malignant cells or if normal human leukocytes dis-
seminate via chicken lymphatics as well. If so, the CAM
might be a suitable model for studies on B-cell homing.
In summary, our data show that the CAM is an excel-
lent model to study tumor-stroma interactions with a
focus on tumor angiogenesis, lymphangiogenesis and
metastasis formation. Our results are in concord with
cancer studies employing the CAM and expand the
characterization of the CAM model to hematological
malignancies [9,10,13,15].Conclusions
Our data show that the CAM is an excellent in vivo
model for NHL research, but has until recently been
underestimated with regards to its similarities with pri-
mary human lymphoma. We would like to stress that,
depending on the scientific questions, the CAM model
may well be used instead of mouse models in preclinical
studies. In addition to the pros illustrated above, further
advantages of the CAM are the low costs per animal,
the convenient handling and the minor bureaucratic ef-
fort (summarized in Table 2). For the testing of new
drugs, the CAM model can be interposed between cell
culture and mouse experiments to serve as an in vivo
screening platform [13,15], as we have recently shown
for the anti-tumor drug imipramine-blue [10]. This
might save scientific resources and accelerate the devel-
opment of new chemotherapeutics due to the higher
throughput and the earlier focus on promising drugs,
especially those that may alter their effectiveness due
to tumor-stroma interactions. Additionally, real-time
imaging approaches of cells migrating within thelymphatics can be used to study the mechanisms of lym-
phogenic metastasis, and probably B-cell homing.
Additional files
Additional file 1: Figure S1. Characterization of BL2 cell line stably
expressing GFP. A: Map of pGIPZ (Thermo Scientific) used for lentiviral
transduction of BL2 to express a scrambled control shRNA (non-silencing
control, ns-c) along with GFP. B: Flow cytometry illustrating GFP
fluorescence in BL-2 ns-c* GFP cells (BL2-GFP) in comparison to the
parental cell line BL-2. C: Immunoblot analysis of Bcl-6 and c-Myc in cell
lysates showing that stable lentiviral transduction had no influence on
protein levels of these transcription factors in two independently
established GFP expressing BL-2 cell lines. Alpha-Tubulin served as
loading control. D: Expression of control shRNA-GFP in two transfectants
(BL-2 ns-c GFP and BL-2 ns-c* GFP) did not alter cell proliferation
according to 3H thymidine assay. Shown is the relative thymidine uptake
within 16 h. The level in BL-2 was set to 1.
Additional file 2: Figure S2. Exo ovo chick chorioallantoic membrane
assay. A-G: Pictures show chick embryos grown outside of the eggshell
(ex ovo). The incubation day is indicated in the lower right corner. Insert
in A shows the extension of the allantois. H: Chicken embryo in a
weighing boat placed in a cell culture flask with a reclosable lid. I: Tumor
cell inoculation on a d11 embryo. Arrow shows the site of tumor cell
engraftment (50% Matrigel) and dotted lines show sites of direct cell
applications (0% Matrigel, 106 cells in 10 μL BL medium).
Additional file 3: Figure S3. Intravital imaging of BL2-GFP cells in the
ex ovo CAM model. A-D”: Time lapse images of BL2-GFP cells, which were
grafted in 50% Matrigel on the CAM. BL2-GFP cell show a bright green
fluorescence, CAM tissue shows a weak greenish autofluorescence, and
blood vessels appear black. Pictures were taken every 24 h, beginning
48 h post inoculation (p.i.). The magnification of the pictures is indicated.
The yellow rectangles in A, A’ and B mark regions shown at higher
magnification in B-D. E-G show distant micrometastases of the specimen
shown in A.
Additional file 4: Figure S4. Immunofluorescence staining of CAM. A:
Prox1 stains nuclei of lymphatic endothelial cells. B: DAPI staining shows
blood vessels, due to the nucleated chick erythrocytes. C: Merged picture
illustrates the close proximity of lymphatics and blood vessels. Larger
blood vessels are flanked by lymphatic collectors.
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